Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avanafil - VIVUS

Drug Profile

Avanafil - VIVUS

Alternative Names: RAZATUS; Spedra; Stendra; TA-1790; Zepeed

Latest Information Update: 14 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Acerus Pharmaceuticals; Endo International; JW Pharmaceutical; Menarini; VIVUS
  • Class Erectile dysfunction therapies; Pyrimidines; Small molecules
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Erectile dysfunction

Highest Development Phases

  • Marketed Erectile dysfunction
  • Discontinued Female sexual dysfunction; Premature ejaculation

Most Recent Events

  • 27 Jun 2019 Preregistration for Erectile dysfunction in Canada (PO)
  • 27 Jun 2019 Health Canada accepts NDS for Avanafil for Erectile dysfunction for active review and completes initial screening
  • 14 Mar 2019 Registered for Erectile dysfunction in Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top